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Abstract: Alignment-free, three dimensional structure–activity relationships 
(3D QSAR) of the antiproliferative potency of twenty-two glutarimide-con-
taining compounds, taken from National Cancer Institute Developmental the-
rapeutics Program database, toward eight representative human tumour cell 
lines are reported. The descriptors used in the QSAR study were derived from 
GRID molecular interaction fields. The obtained models readily detect struc-
tural motifs positively or negatively correlated with the potency of the studied 
compounds toward each cell line. In this way, the pharmacophoric pattern 
required for high potency of compounds is reported. This pattern can serve as 
guidance for the design and syntheses of novel congeners, planned to be tested 
toward human tumour cell lines. 
Keywords: glutarimides; antiproliferative agents; alignment-independent 3D 
QSAR; GRIND descriptors. 
INTRODUCTION 
Nitrogen-containing heterocyclic systems having different pharmacological 
activities are widespread among alkaloids. Five- and six-membered cyclic imide 
derivatives are a valuable group of bioactive compounds, which act as androgen 
receptor antagonists, anti-inflammatory agents, anxiolytics, antivirals, antibacte-
rials, and tumour suppressing agents.1 These compounds rarely occur in natural 
sources and most of them are made synthetically.  
Cancer may affect people at all ages, animals or even plants; it causes about 
13 % of all human deaths. Consequently, huge efforts are being made in the 
search for and exploration of new antitumour agents. In light of the present re-
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cession in the world and the reduction of financing in R&D, all pharmaceutical 
companies retain the development of antitumour agents as top priority projects. 
Some naturally occurring glutarimides, such as sesbanimides, cycloheximi-
de, and streptimidone, were investigated as antibiotics during the 60–70s of the 
last century. Later, it was discovered that they act as very potent cytotoxic 
agents.2,3 Recent research in the field of human medicine shows that cyclohex-
imide increases the cytotoxic effect of the recombinant human tumour necrosis 
factor-α (rHuTNF-α) to nasopharyngeal carcinoma cells (NPC).4 The structurally 
related streptimidone derivative, 9-methylstreptimidone (9-MS), exerts signifi-
cant inhibitory activity to the cancer and inflammatory cells activated nuclear 
factor-κB (NF-κB).5 
The non-steroidal aromatase inhibitor aminoglutethimide is used for the treat-
ment of Cushing’s syndrome6 and hormone-sensitive metastatic breast cancer.7,8 
Estrone derivatives with the D-ring replaced with the glutarimide ring have 
shown potent inhibition of steroid sulphatase, an enzyme which is involved in the 
pathway of the development of hormone-dependent breast tumours (HDBT).9 
2-Phenylamino-imidazo[4,5-h]isoquinolin-9-ones, inhibitors of kinase p56 (lck) 
in T-cells, were recently reported as potential therapeutic agents in the treatment 
of different autoimmune diseases.10 
The GRIND, alignment independent, interpretable and efficient to compute 
descriptors derived from GRID molecular interaction fields, was proved relevant 
in diverse structure–activity relationship studies. The GRIND was used for struc-
ture–activity relationships in receptors or enzymes, the classification of large struc-
turally diverse datasets by pharmacophore similarity and virtual screening.11 Re-
garding the antiproliferative activity of organic compounds, the structure-based 
rationalization of the mechanism of action of antitumour drugs on NCI-DTP 
screening data was reported,12 together with case studies of potent antiprolife-
rative imidazolium derivatives13 and histone deacetylase inhibitors.14 
Continuing our interest in glutarimide derivatives,15 a structure–activity stu-
dy is reported herein on the antiproliferative activity of a set of glutarimide-con-
taining compounds (1–22) toward K562 (leukaemia), A549ATCC (non-small 
cell lung), malme-3M (melanoma), COLO205 (colon), UO31 (renal), U251 
(CNS), IGROV1 (ovarian), and MFC-7 (breast) human tumour cell lines; which 
are described in the text as models A–H, respectively. Data were taken from the 
US National Cancer Institute (NCI) Developmental Therapeutics Program 60 
human tumours cell line screen database (NCI60).16 The results obtained in this 
study could be a guidance for the design of novel congeners with expected anti-
proliferative activity. To the best of our knowledge, structure–activity relation-
ships of the antiproliferative potency of glutarimide derivatives cannot be found 
in the literature. 
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RESULTS AND DISCUSSION 
Aimed at finding the pharmacophoric pattern of glutarimide derivatives res-
ponsible for their significant antiproliferative activity, alignment-independent 3D 
QSAR models for the potency of 1–22 toward representative cell lines were ob-
tained. The criteria for the selection of the compounds are given in the Experi-
mental. Within each category, the cell line towards which most of the glutarimide 
derivatives exert activity were chosen. The structures and classification of the 
compounds are given in Table I. 
Methodology 
The program Pentacle17 uses alignment independent descriptors derived 
from GRID18 molecular interaction fields (MIF). A more negative value of GRID 
MIF for any used probe corresponds to a more favourable interaction between the 
TABLE I. Structures of 1–22 used in the models 
Class No.
. Structure  Compound  No. 
I 
N
H
R
O O
  O H
OH
OH
R = 
1 
O H
OH
R = 
2 
O H
OH
OCOMe
R=
3 
II 
N
H
O O
R1 R
CN NC
R = Me–  4 
R1 = 2-Cl–Ph– 
R = Me–  5 
R1 = 4-F–Ph– 
III 
N
H
O O
R2
R1
R1 = n-hept– 
R2 = 4-NH2–Ph– 
6 
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TABLE I. Continued 
Class No.
. Structure  Compound  No. 
IV 
N
H
O O
R R = –OC(O)Me  7 
R = –OH  8 
V  R1
N O O
R  
R = –CH2CH2–Pyr 
R1 = –O–Me 
9 
R = H– 
R1 = –O–Me 
10 
R = Me– 
R1 = –O–Me 
11 
R = n-Bu– 
R1 = –O–n-Bu 
12 
R = n-Bu– 
R1 = –O–CH2CH2–Pyr 
13 
R= -O-CH2CH2–Pip 
R1= –O–Me 
14 
R = –NH2 
R1 = –O–Me 
15 
VI 
N
H
O O
R
 
OH O
R=
16 
OH O
R=
17 
VII 
N
H
O O
R1
R
 
R = –C(O)O–t-Bu 
O
O
Ph
Ph
R1=
18 
VIII 
N
H
O O
R
R1
 
N
O
O
NO2
R1=
R = Et– 
19 
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TABLE I. Continued 
Class No.
. Structure  Compound  No. 
IX 
N O O
R1
R  
R = Ph– 
O R1=
t-Bu
20 
R= Ph– 
O H
O H
R1=
t-Bu
21 
X 
N
H
O O
R
 
O
O O
O H
OH
R=
22 
probe (e.g., hydrogen bond donor, hydrogen bond acceptor, hydrophobic) and a 
molecule for which the GRID MIF was calculated. By calculating MIFs for dif-
ferent GRID probes around the molecule and extracting the most relevant re-
gions, a fingerprint of a receptor to which a small molecule could fit well can be 
obtained. These regions show favourable energy of interaction and represent po-
sitions where groups of a potential receptor would interact favourably with a li-
gand. Such an MIF pattern can be described as the virtual receptor site (VRS). 
Each GRIND descriptor consists of two nodes extracted from MIFs and encodes 
their energy product and spatial distance. GRIND variables represent geometrical 
relationships between relevant pharmacophore points around the studied mole-
cules, which are invariable with respect to the position of the molecule in space 
and their alignment. The derivation of GRIND descriptors includes the following 
steps: i) computing a set of MIF around the studied molecules, ii) filtering the 
MIF, to extract the most relevant regions that define the VRS and iii) encoding 
the VRS into the GRIND variables. GRIND variables can be used for compa-
rison of molecules and their classification within sets of structurally diverse en-
tities and the Pentacle program uses principal component analysis (PCA) for this 
type of analysis. A dependent variable (e.g., biological activity) can be correlated 
to GRIND descriptors (as independent variables) obtained on a set of molecules 
by partial least square analysis (PLS). The most intensive bars in the PLS plots 
have the highest impact on the model. Bars having positive values on the y scale 
represent variables positively correlated with activity, while those having nega-
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tive values on y scale are negatively correlated with activity. Within each block 
(auto or cross-correlograms, which correspond to pairs of nodes of the same or a 
different probe, respectively) variables are arranged from left to right on the x 
scale of the plot according to ascending distance between their nodes. In addition 
to the spatial arrangement of molecules and nodes encoded in the GRIND vari-
ables, each node of each variable exerts a specific energy of interaction with a 
target molecule. Therefore, the strength of the interaction between a respective 
GRID probe in a particular node and the molecules are presented as well as the 
spatial positions of the VRS regions. 
The NCI60 anticancer drug screen16 was developed in the late 1980s, and 
was quickly recognized as a rich source of information concerning the mecha-
nisms of growth inhibition and tumour-cell kill. Recently, its role has evolved to 
that of a service screen supporting the cancer research community. 
Structure–activity relationship 
The potencies of compounds, given as p(GI50), the negative logarithm of the 
molar concentration that induces a 50 % reduction of the respective cell growth, 
are given in Table I-S in the Supplementary material. Eight models were built. 
All the studied compounds (1–22) exhibited a similar order of potency towards 
each cell line, as can be seen from Table I-S, and the intercorrelation matrix of 
the p(GI50) values for all the studied cell lines (Table XV-S). As all the obtained 
models were similar in their important parts, a detailed description of the model 
on the antiproliferative potency of 1–22 towards the K562 cell line is given and 
explained. For the other cell lines, the partial least square coefficient plots, sta-
tistical data, and the expression of variables for each compound are given in the 
supplementary material in tabular format. 
The variables of the models positively or negatively correlated with activity 
readily detected the structural motifs of compounds 1–22 that contribute to po-
tency. The smaller molecules were more potent towards all the studied cell lines. 
Molecules containing both the glutarimide moiety and a HBA, mainly the hyd-
roxyl group, on a spatial distance of ∼11 Å expressed higher potency. On the con-
trary, larger molecules and those with bulky substituents at a distance of ∼20 Å 
from the glutarimide moiety were significantly less potent. The characteristic PLS 
plot obtained with 4 latent variables (LV) for the K562 model is given in Fig. 1d. 
– All the described structural motifs of the compounds important for the 
antiproliferative potency are anchored to the glutarimide moiety that comprises 
HBA, HBD, and hydrophobic parts. 
– Two hydrophobic moieties, one of which is associated with alkyl part of 
the glutarimide ring and the other with the distal (8.32–8.64 Å) π systems of the 
molecules, are negatively correlated with the potency of the compounds – vari-
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able DRY–DRY 26 (Fig 1a). Accordingly, this variable is not expressed for the 
most potent 22. 
– Compounds that comprise two HBD groups at a distance of ∼11 Å exert 
higher potencies. One HBD is always glutarimide, –NH–, while the other is hyd-
roxyl group, positioned at the topological distance of five bonds for 22, or at the 
methylene bridge for 1–3 (Table I), as given by the variable O–O 111, Fig. 1b. 
 
Fig. 1. Examples of variables that have a high impact on the model, associated with 
compounds: a) variable DRY–DRY 26 for 21; b) variable O–O 111 for 22; c) variable N1–N1 
205 for 3; d) 4 LV PLS coefficient plot for the K562 model; e) variable TIP–TIP 290 for 16; 
f) variable O–TIP 672 for 21; g) variable N1–TIP 746 for 10. 
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– Two HBA groups at a distance of ∼16.8 Å are the next structural motif 
positively correlated with activity, as given by variable N1–N1 205, Fig. 1c. This 
variable exists only for compounds of class V and compounds 1 and 3, which 
belong to the most potent class I. For compounds of class V, one HBA is always 
glutarimide >C=O and the other is an alkoxy group, except for compound 13, 
which is more potent than the other members of this class. In this point, the mo-
del recognized the HBA of the pyrrolidino substituent in place of the alkoxy 
group of the other compounds within class V. In 1 and 3 (class I), the other HBA 
is the distal –OH or the carbonyl oxygen of the methyl ester, respectively.  
– All structural motifs, as described above, that have a significant impact on 
the models emphasize that all highly potent molecules bear similar spatially po-
sitioned HBD–HBD and HBA–HBA combinations, as exemplified in Figs. 1b 
and 1c. 
– The bulkier compounds exhibited a lower potency (p(GI50) < 6), as can be 
seen from the variable TIP–TIP 290, Fig. 1e. The glutarimide ring distal from 
bulky substituents, i.e., a terminal methyl or t-butyl group; or the glutarimido-
naphthyl moiety (classes VI, VIII and IX, respectively), negatively influences the 
potency. Molecules of the most potent classes (I and X) and some less potent mo-
lecules from classes III and IV lack bulky substituents distal from the glutarimide 
moiety. 
– Similar information encoded in variables that have the highest positive im-
pact on the model (O–O 111, N1–N1 205) could be obtained from the additional 
variables O–N1 590 and O–TIP 638, respectively. Therefore, HBA and HBD of 
molecules positioned at a spatial distance of ∼16.8 Å significantly contribute to 
the potency. The variable O–N1 590 is expressed for the potent 1 and 3 (class I), 
as well as for 10 and 15 (class V), see Table VII-S. Implicitly, compounds from 
class V that have similarly positioned HBA and HBD as in compounds of class I 
but a rigid backbone exhibit lower potencies. Together with this, structural motifs 
comprising HBD at ∼7.2 Å from the non-polar part of the molecules contribute to 
the potency. 
– Variables O–TIP 672 and N1–TIP 746 offer similar information as the va-
riable TIP–TIP 290. Those variables show that compounds having bulky sub-
stituents (TIP) distal from the glutarimide moiety (O or N1) have lower potency. 
The structural differences between the most and the least potent compounds 
can be clearly seen from Pentacle heatmaps (see the experimental for an expla-
nation of matrix representation of correlograms). The heatmaps for the whole set 
(1–22) are presented in Fig. 2. The compounds are arranged by decreasing po-
tencies, from top to bottom. A distinct band of O–O correlograms exists for the 
most potent compounds (yellow framed), which is consistent with the signifi-
cance of the O–O variables that have a strong positive impact on the model. For 
the other compounds, the regions of the same correlograms are less populated. 
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Fig. 2. Matrix-like representa-
tion (heatmaps) of the auto- and 
cross-correlograms of 1–22. 
                      
 (a)  (b) 
Fig. 3. Auto- and cross-correlograms of compounds a) 22 and b) 11, labelled as follows: 1 
DRY–DRY, 2 O–O, 3 N1–N1, 4 TIP–TIP, 5 DRY–O, 6 DRY–N1,  
7 DRY–TIP, 8 O–N1, 9 O–TIP and 10 N1–TIP. 
Together with this, the bands of the TIP–TIP correlograms are broader for the 
larger, less potent compounds; while the band of the N1–TIP block is narrower 
for the most potent compounds (framed green), which is consistent with the des-
cription of the N1–TIP variables that describe larger node–node distances, and 
has a high negative impact on potency in all models. As an additional illustration, 
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all auto- and cross-correlograms for the most (22), and one of the least potent 
(11) compounds are given in Figs. 3a and 3b, respectively. Comparing the most 
important differences in the pattern of the most 22 and less potent 11, it is evident 
that the less active compound lacks two HBD (empty O–O block (2)) and the lar-
ger strong peaks in the TIP–TIP block (4) are positioned to the right with respect 
to the same block of 22. Additionally, there is significantly larger distance be-
tween one HBA and the distal part of molecule in the less potent 11 than in 22, as 
shown by the strong peaks in the N1–TIP block (10), positioned to the right for 
11 compared to 22. 
To summarize the observations mentioned above, two plots are presented in 
Fig. 4 in which the potency of the compounds (p(GI50)) is plotted vs. the mole-
cular volume and vs. the distance between the glutarimide moiety and the distal 
HBA or HBD. A clear separation of the most potent compounds was achieved in 
this way. 
 
 (a)  (b) 
Fig. 4. a) p(GI50) vs. volume of 1–22. The compounds are coloured according to their 
increasing potencies, in the following order: purple–pink–green–orange. b) p(GI50) vs. 
HBA/HBD distance, given as: HBD–HBD of the compounds associated to 
the variable O–O 111 (orange spheres) and HBA–HBA of the compounds 
associated to the variable N1–N1 205 (green stars). 
EXPERIMENTAL 
The NCI-DTP Database was searched for structures comprising the glutarimide moiety 
(substructure query as SMILES notation: O=C1CCCC(=O)N1). All compounds that matched 
the query were saved (1–22) and their potency expressed as p(GI50) against: leukaemia K562 
(A); non small cell lung A549ATCC (B); colon COLO205 (C); CNS U251 (D); melanoma 
malme-3M (E); ovarian IGROV1 (F); renal UO-31 (G) and breast MCF-7 (H) tumour cell 
lines extracted. SMILES Notation of 1–22 was converted to 3D by CORINA.19 Each initial 
3D structure was imported in VegaZZ20 and twenty conformations that represent local minima 
were obtained by conformational search on the MM level (MMFF94s force field),21 using the 
Boltzmann jump algorithm in AMMP.22 Each conformation of each compound was mini-
_________________________________________________________________________________________________________________________ Available online at www.shd.org.rs/JSCS/
2010 Copyright (CC) SCS  SAR OF ANTIPROLIFERATIVE GLUTARIMIDE DERIVATIVES  1177 
mized by the semi-empirical molecular orbital PM6 method,23 using implicit solvation in 
water (COSMO) to root mean square gradient of 0.01; by MOPAC2009.24 The obtained con-
formation of each compound that had the lowest heat of formation (implied the most stable 
one) were chosen for model building. All molecules were treated in their neutral form. 
For alignment-free 3D QSAR analysis, the molecules were submitted to Pentacle.17 The 
molecular interaction fields were computed using the built-in GRID program,18 with a grid 
resolution of 0.4 Å. AMANDA algorithms were used for the extraction of hot spots (nodes) 
from the obtained MIFs (discretization); the distances and relative position of the nodes were 
described by maximum auto and cross-correlation (MACC2) (encoding). For details, see the 
original reference.17 Five principal components/latent variables were used for the initial prin-
cipal component analysis (PCA) and partial least square (PLS) model. Selection of the vari-
ables was realised by one cycle of factorial fractional design (FFD) for the models A–H. Vali-
dation of the models was performed by cross validation using four groups of approximately 
the same size in which the objects are assigned randomly. The final models were obtained 
with 3 or 4 latent variables (LV). 
A detailed explanation of auto- and cross-correlogram in the ALMOND program can be 
found in the original reference25 and the program manual available from the Molecular Dis-
covery web site. Exactly the same correlograms can be found in Pentacle, with the option of a 
matrix-like presentation of the auto- and cross-correlograms for all compounds, named heat-
maps, as depicted in Fig. 2. In the matrix-like representation, every row represents a single 
compound and every column a single variable. The values of the variables are colour-coded 
from red (low value) to blue (high value). 
Details of the procedure for the determination of GI50 values can be found at: http:// 
//dtp.nci.nih.gov/branches/btb/ivclsp.html and in the literature.26 
CONCLUSIONS 
It can be concluded that, generally, smaller molecules are more potent to-
wards all studied cell lines. Molecules containing the glutarimide moiety at a 
distance ∼11 Å, or 5 topological bonds, to a HBA (mainly hydroxyl group) ex-
press higher potencies. On the contrary, larger molecules and those with bulky 
substituents at a distance ∼20 Å from the glutarimide moiety are significantly less 
potent. In addition, it was noticed that within a subset having a favourable phar-
macophore pattern, as described above, molecules possessing a flexible backbone 
(classes I and X) are more potent than rigid tetracyclic molecules (class V). 
These conclusions will be guidance for the selection of compounds previously 
prepared for in vitro antitumour screening; as well as for the design and synthe-
ses of novel compounds that could express significant potency towards dediffe-
rentiated human cells. 
SUPPLEMENTARY MATERIAL 
Associated with this article; p(GI50) values for 1–22 towards cell lines A–H, PCA 
models, PLS models, PLS plots, structural motifs associated with important variable for the 
cell line models A–H, association of variables with 1–22 for cell line models A–H and the 
intercorrelation matrix of p(GI50) values for all the reported cell lines are available electro-
nically from http://www.shd.org.rs/JSCS/, or from the corresponding author on request. 
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ИЗВОД 
АНТИПРОЛИФЕРАТИВНА АКТИВНОСТ ГЛУТАРИМИДНИХ ДЕРИВАТА ИЗ БАЗЕ 
ПОДАТАКА НАЦИОНАЛНОГ ИНСТИТУТА ЗА РАК, САД. 3Д ОДНОС СТРУКТУРЕ И 
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У тексту је описан однос структуре и антипролиферативне активности 22 глутаримидна 
деривата према осам репрезентативних линија хуманих тумора. Подаци о структури једи-
њења и њиховој активности су преузети из базе података Националног Института за рак, 
САД.  Дескриптори,  независни  од  поравнавања  молекула (GRIND-2), коришћени  у  проу-
чавању односа структуре и активности су добијени употребом програма GRID. Модели јасно 
приказују  структурне  елементе  једињења  који  се  позитивно  или  негативно  корелишу  са 
биолошком  активношћу.  Фармакофорна  слика  добијена  из  модела  ће  бити  коришћена  за 
планирање нових аналога који садрже глутаримидни прстен и за које се очекује да ће пока-
зати значајну антипролиферативну активност. 
(Примљено 2. децембра 2009, ревидирано 25. јануара 2010) 
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